|View printer-friendly version|
|October 01, 2004 5:17 p.m.|
|Teva Announces Approval Of Mesalamine Rectal Suspension Usp|
Jerusalem, Israel, October 1, 2004 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted final approval for the company's ANDA for Mesalamine Rectal Suspension, USP, 4 gm/60 mL. Shipment of this product is expected to begin immediately.